Og mens vi er inne på Mesotheliom er det kanskje relevant og ta frem en av årsakene til at de valgte å gå videre med indikasjonen etter fase 1:
Denne pasienten oppnådde de SD.
"This case report describes how treatment with ONCOS-102 in a 68-year-old male with
asbestos-related malignant pleural mesothelioma, resulted in prominent infiltration of CD8+ lymphocytes to tumor, marked induction of systemic antitumor CD8+ T-cells and induction of Th1- type polarization in the tumor in addition to a 47% reduction of the size of the tumor.
• Use of adenoviruses as cancer vaccines is a form of active immunotherapy to initialise a tumor-specific immune response that targets the patient’s unique tumor
antigen repertoire.
• These results indicate ONCOS-102 treatment sensitizes tumors to other
immunotherapies by inducing a T-cell positive phenotype to an initially T-cell
negative tumor
• Patient survived 18 mo (542 d) from treatment initiation and over 33 mo (999 d) from diagnosis - remarkable given median survival of patients with malignant pleural
mesothelioma varies from 4 to 12m from diagnosis."
Håper vi kan gjenskape noe liknende i den randomiserte studien.
…